NCT07033533

Brief Summary

Hepatic decompensation is a common healthcare issue . This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Jun 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2023

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2024

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

June 14, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 24, 2025

Completed
Last Updated

June 24, 2025

Status Verified

June 1, 2025

Enrollment Period

9 months

First QC Date

June 14, 2025

Last Update Submit

June 14, 2025

Conditions

Cirrhoses, Liver

Outcome Measures

Primary Outcomes (1)

  • biomarkers as zonulin, LPS, MMP-13, MDA

    6 MONTHS

Study Arms (2)

placebo

PLACEBO COMPARATOR

placebo

Drug: Placebo

allopurinol

ACTIVE COMPARATOR
Drug: Allopurinol Tablet

Interventions

Allopurinol TabletDRUG

allopurinol 300

allopurinol
PlaceboDRUG

placebo tablet

placebo

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age 18-75 both sex

You may not qualify if:

  • active GIT bleeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tanta University

Tanta, Egypt

Location

MeSH Terms

Interventions

Allopurinol

Intervention Hierarchy (Ancestors)

PurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
dr

Study Record Dates

First Submitted

June 14, 2025

First Posted

June 24, 2025

Study Start

June 1, 2023

Primary Completion

March 1, 2024

Study Completion

March 1, 2024

Last Updated

June 24, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations

EG(1)